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Table 1.Test formulations composed of five causal factors based on an L16 (25)
fractional factorial experimental design and their response variables 
?  Causal factors Response variables 
Rp.
X1
X2 X3 X4 X5 D10 D60 TS f2
(%) (%) (%) (kN) (%) (%) (MPa) (%) 
1 SD 1 5 5 8 24.7±2.0 49.7±2.1 1.002±0.065 41.5±3.3
2 SD 1 5 15 12 17.6±1.1 56.7±1.9 1.337±0.069 41.6±1.0
3 SD 1 15 5 12 29.9±3.1 63.6±4.8 1.026±0.068 58.5±9.6
4 SD 1 15 15 8 36.0±4.5 59.6±1.9 1.093±0.066 51.9±1.8
5 SD 3 5 5 12 25.3±0.8 67.8±1.5 0.658±0.119 53.5±8.9
6 SD 3 5 15 8 41.6±3.5 68.0±2.4 0.447±0.031 75.3±9.6
7 SD 3 15 5 8 41.5±2.8 69.8±2.4 0.522±0.041 72.7±10.0
8 SD 3 15 15 12 19.6±1.6 66.8±4.5 0.601±0.011 47.8±3.3
9 PM 1 5 5 12 19.3±1.9 30.5±0.5 0.882±0.065 82.2±8.2
10 PM 1 5 15 8 21.4±0.4 31.4±0.5 0.844±0.043 69.6±0.9
11 PM 1 15 5 8 17.1±1.5 29.1±0.1 1.100±0.095 78.0±6.6
12 PM 1 15 15 12 18.9±1.7 30.5±0.7 1.480±0.037 76.8±2.8
13 PM 3 5 5 8 21.8±2.0 37.9±0.4 0.540±0.118 79.3±4.3
14 PM 3 5 15 12 20.4±5.8 40.9±4.3 0.770±0.063 74.7±5.0
15 PM 3 15 5 12 17.7±2.2 38.7±0.9 1.055±0.103 74.9±6.2
16 PM 3 15 15 8 21.2±3.7 39.1±0.3 1.017±0.063 70.8±7.3
X1 is the IMC tablets prepared as solid dispersions (SD) or physical mixture (PM). 
X2 is the quantities of magnesium stearate (Mg-St). X3 is the quantities of 
microcrystalline cellulose (MCC). X4 is the quantities of low-substituted 
hydroxypropyl (L-HPC). X5 is the compression force. D10 and D60 are dissolution 
rates at 10 and 60 min, respectively. TS is tensile strength. f2 is similarity factor. 
Figure 1. Network models between causal factors
and responses estimated by (a) ANOVA and (b)-(d)
BN models based on three judging standards (b) A
kaike’s information criterion (BN-AIC), (c) minimum
description length (BN-MDL), and (d) maximum log
likelihood (BN-ML). The nodes correspond to the
causal factors and pharmaceutical responses, re-
spectively, and the links represent the dependencies
between them.
Figure 2. Conditional probability distributions
(CPDs) of causal factors inferred by BN. CPDs of
the causal factors were estimated for the best com-
bination of response variables, such as high values
for D10, D60, TS, and f2.









? ?LAC?? ??????? ?CS?? ???????
?MCC? ????? ????????????? ? 9?
????????????? ????????????
30??????????? RSM-S?????????
??? ?Figure 3?? ???? MCC????????
???????????? ?????????????
????????? ?????????MCC????













?? ??? BS????? DS???????????
?? Figure 4? BS????????? ??? ???
???????????? BS ???????? 500
?????? ??? 500 ?? BS ????????
RSM-S????? ????? DS??????? ??
?????????? ???? ?????? 95???
???????? DS???????????








????? RSM-S? BS?????? DS????
???????????????? ??? ??????
???? 95??????????? ?????? 99.9
Proc? Hoshi Univ. No.56, 2014
? ?? ?
Figure 3. Resampling process for evaluating the re-
liability of the border of the design space estimated
by RSM-S.
 
Figure 4. Response surfaces of the indomethacin
tablets estimated by RSM-S as a function of the
amounts of lactose, cornstarch (CS), and
microcrystalline cellulose (MCC). (a) and (b) indi-
cate hardness before and after the accelerated test,
respectively. (c) and (d)indicate the dissolution rate
30 min before and after the accelerated test, respec-
tively.
 
Figure 5. Conservative design space comprising su-
perimposed individual design spaces for hardness
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Figure 6. Flow chart of the granulation process.

















1 30 1 4 1.5 0.85±0.01 9.24±0.06
2 30 9 4 1.5 1.12±0.03 13.65±0.11
3 40 1 4 1.5 1.00±0.08 13.76±0.16
4 40 9 4 1.5 1.28±0.04 15.56±0.15
5 35 5 3 0.5 0.74±0.00 13.69±0.30
6 35 5 3 2.5 0.81±0.02 11.33±0.15
7 35 5 5 0.5 1.42±0.03 14.82±0.08
8 35 5 5 2.5 1.51±0.08 18.07±0.26
9 30 5 4 0.5 0.99±0.04 11.27±0.20
10 30 5 4 2.5 1.10±0.05 12.22±0.20
11 40 5 4 0.5 1.20±0.07 14.16±0.16
12 40 5 4 2.5 1.33±0.06 15.80±0.17
13 35 1 3 1.5 0.68±0.00 8.85±0.11
14 35 1 5 1.5 1.17±0.06 12.14±0.38
15 35 9 3 1.5 0.74±0.03 11.53±0.23
16 35 9 5 1.5 1.47±0.09 15.31±0.22
17 30 5 3 1.5 0.75±0.00 9.49±0.25
18 30 5 5 1.5 1.36±0.05 14.72±0.20
19 40 5 3 1.5 0.94±0.01 12.75±0.25
20 40 5 5 1.5 1.65±0.06 18.84±0.19
21 35 1 4 0.5 0.79±0.05 9.55±0.25
22 35 1 4 2.5 0.91±0.03 11.74±0.25
23 35 9 4 0.5 1.08±0.02 13.09±0.12
24 35 9 4 2.5 1.17±0.02 13.31±0.08
25 35 5 4 1.5 1.16±0.05 12.63±0.21
26 35 5 4 1.5 1.17±0.05 12.50±0.23
27 35 5 4 1.5 1.13±0.02 12.71±0.20
X1 is water amount. X2 is kneading time. X3 is compression force. X4 is amount of Mg-
St. TS is tensile strength. DT is disintegration time. The value of TS and DT represent
the mean ± S.D. for three determinations. 
 
 
Figure 7. Bayesian network model of the latent
structure among process parameters, granule prop-
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Figure 8. Conditional probability distributions
(CPDs) of causal factors inferred using a Bayesian
network model. Compression pressure and amount
of -mannitol were set as prior probabilities. The
CPDs of the causal factors were estimated for two
cases: intermediate compression force and low
amount of-mannitol, and intermediate compression
force and high amount of -mannitol.
Figure 9. Flow chart of the finite element analysis:
a typical finite element model for modeling the
compaction of flat-faced tablets, the model at the
point of maximum compression and the model dur-
ing decompression. The powder was modeled using
the DPC model. An axisymmetric two-dimensional
model (right half) was used.
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Figure 10. Two-dimensional maps for the residual
stress distribution of tablets estimated using the
FEM: (a) x axial stress (x), (b) y axial stress (y)
and (c) shear stress () of Rp. 2. (d) x axial stress
(x), (e) y axial stress (y) and (f) shear stress ()
of Rp. 4.
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Development of novel QbD methods for
understanding manufacturing process of pharmaceutical products
Yoshihiro HAYASHI
Department of Pharmaceutics, Hoshi University
In recent years, regulatory authorities such as the US Food and Drug Administration and the International Conference on
Harmonisation (ICH) have promoted and requested the application of quality-by-design (QbD) principles.This requires the use
of a combination of chemometric treatments, including the design of experiments (DOE), the response surface method (RSM),
and multivariate analyses. To date, various results have suggested that a nonlinear response surface method incorporating
multivariate spline interpolation (RSM-S) is a potential tool for pharmaceutical tablet manufacturing process.However, several
difficulties are yet to be overcome regarding a non-linear technique such as RSM-S. The purpose of this study was to overcome
problems and establish valuable tools for the pharmaceutical design under the QbD concept.First, I attempted to clarify the la-
tent structure underlying the causal factors and pharmaceutical responses of a tablet using a Bayesian network (BN). Sec-
ondly, a reliability of border on the design space estimated by RSM-S was evaluated using a resampling method with replace-
ment. Then, a multivariate statistical technique was applied to the design of an orally disintegrating tablet and to clarifying
the causal correlation among variables of the manufacturing process and pharmaceutical responses. Finally, the mechanical
behavior of pharmaceutical powders during compaction was analyzed using the finite element method (FEM). In conclusions,
these findings suggest that proposed novel multivariate statistical approaches and numerical analysis method are useful tools
for the pharmaceutical design under the QbD concept.
